We have recently shown that MYC as oncogenic protein di per se and a MYC-dependent gene signature cooperate with gain of function TP53 mutations to foster HNSCC proliferation and to increase resistance to the treatment [24]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.